REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

25 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 Mar 2025 13:10:05 By NetDania Notify

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

11 Mar 2025 20:32:16 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08 Mar 2025 12:00:00 By Nasdaq GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

28 Feb 2025 06:00:02 By Nasdaq GlobeNewswire

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

26 Feb 2025 06:00:19 By Nasdaq GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

24 Feb 2025 14:00:04 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

17 Feb 2025 23:59:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

11 Feb 2025 06:00:39 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 Feb 2025 16:40:16 By Nasdaq GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08 Feb 2025 14:55:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 Feb 2025 08:45:06 By NetDania Notify

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

04 Feb 2025 05:30:01 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 Feb 2025 08:46:44 By NetDania Notify

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

23 Jan 2025 11:00:14 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Jan 2025 08:45:01 By NetDania Notify

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

13 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

13 Jan 2025 05:15:45 By Nasdaq GlobeNewswire

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

13 Jan 2025 05:05:00 By Nasdaq GlobeNewswire